Cargando…

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis

Nitazoxanide (NTZ) is an FDA-approved anti-parasitic drug with broad-spectrum anti-infective, anti-inflammatory, and antineoplastic potential. However, its regulatory effects on osteoclastogenesis and the underlying mechanisms remain unclear. The present study found that NTZ potently inhibited osteo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chang-hong, Lü, Zi-rui, Zhao, Zhen-da, Wang, Xin-yu, Leng, Hui-jie, Niu, Yan, Wang, Mo-pei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696474/ https://www.ncbi.nlm.nih.gov/pubmed/34955850 http://dx.doi.org/10.3389/fphar.2021.781640

Ejemplares similares

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis
por: Zhong, Zeyuan, et al.
Publicado: (2020)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
por: Wei, Jiyong, et al.
Publicado: (2020)

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis
por: Chen, Xiao, et al.
Publicado: (2017)

BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Cai, Chenhui, et al.
Publicado: (2021)

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021)

PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice
por: Choi, Joo-Hee, et al.
Publicado: (2018)

Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice
por: Zhan, Yunfei, et al.
Publicado: (2020)

Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption
por: Niu, Chenguang, et al.
Publicado: (2017)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
por: Qi, Guobin, et al.
Publicado: (2022)

The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss
por: Feng, Mingzhe, et al.
Publicado: (2023)

Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo
por: Xu, Qiang, et al.
Publicado: (2021)

Theaflavin-3, 3′-Digallate Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Ovariectomy-Induced Bone Loss in Mice
por: Ai, Zexin, et al.
Publicado: (2020)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
por: Hou, Huanhuan, et al.
Publicado: (2020)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
por: Guo, Wen, et al.
Publicado: (2021)

Parkin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss
por: Hou, Weiduo, et al.
Publicado: (2022)

Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways
por: Liu, Yamei, et al.
Publicado: (2022)

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways
por: Wang, Gang, et al.
Publicado: (2022)

Corrigendum: Bushen huoxue decoction inhibits RANKL-stimulated osteoclastogenesis and glucocorticoid-induced bone loss by modulating the NF-κB, ERK, and JNK signaling pathways
por: Liu, Yamei, et al.
Publicado: (2023)

Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation
por: Zhang, Qiang, et al.
Publicado: (2018)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
por: He, Qi, et al.
Publicado: (2022)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

Monascin abrogates RANKL-mediated osteoclastogenesis in RAW264.7 cells via regulating MAPKs signaling pathways
por: Cheng, Yin, et al.
Publicado: (2022)

Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice
por: Goto, Tadashi, et al.
Publicado: (2014)

High-Dose Diosgenin Reduces Bone Loss in Ovariectomized Rats via Attenuation of the RANKL/OPG Ratio
por: Zhang, Zhiguo, et al.
Publicado: (2014)

Antiprotozoal Nitazoxanide Derivatives: Synthesis, Bioassays and QSAR Study Combined with Docking for Mechanistic Insight
por: Scior, Thomas, et al.
Publicado: (2015)

Tectorigenin inhibits RANKL‐induced osteoclastogenesis via suppression of NF‐κB signalling and decreases bone loss in ovariectomized C57BL/6
por: Ma, Chiyuan, et al.
Publicado: (2018)

Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL‐induced osteoclastogenesis
por: Qian, Zhi, et al.
Publicado: (2020)

Poria Cocos Ameliorates Bone Loss in Ovariectomized Mice and Inhibits Osteoclastogenesis In Vitro
por: Hwang, Youn-Hwan, et al.
Publicado: (2020)

Juglanin Inhibits Osteoclastogenesis in Ovariectomized Mice via the Suppression of NF-κB Signaling Pathways
por: Zhang, Fangxue, et al.
Publicado: (2021)

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities
por: Liu, Yuhao, et al.
Publicado: (2019)

Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by Suppressing Osteoclast Activity
por: Zhao, Libo, et al.
Publicado: (2017)

Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
por: Wang, Jia, et al.
Publicado: (2020)

Short-Term Hypoxia Accelerates Bone Loss in Ovariectomized Rats by Suppressing Osteoblastogenesis but Enhancing Osteoclastogenesis
por: Wang, Guixin, et al.
Publicado: (2016)

Deacylcynaropicrin Inhibits RANKL-Induced Osteoclastogenesis by Inhibiting NF-κB and MAPK and Promoting M2 Polarization of Macrophages
por: Li, Zhikun, et al.
Publicado: (2019)

ZhiJingSan Inhibits Osteoclastogenesis via Regulating RANKL/NF-κB Signaling Pathway and Ameliorates Bone Erosion in Collagen-Induced Mouse Arthritis
por: Ling, Yuanyuan, et al.
Publicado: (2021)

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo
por: Peng, Jiaxuan, et al.
Publicado: (2020)

Mining Sudanese Medicinal Plants for Antiprotozoal Agents
por: Mahmoud, Abdelhalim Babiker, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u3e7us4mnc9aggqjl7rae9f0n1